Anderson Kenneth Carl 4

What Happened

• Kenneth C. Anderson, a non-employee director of C4 Therapeutics (CCCC), was granted 2,650 shares of common stock on July 1, 2026. The shares were valued at $4.34 each (based on the July 1 closing price), for a total reported value of $11,501.
• This transaction is an award/grant (compensation) — the director elected to receive stock instead of cash under the company’s Non-Employee Director Compensation Policy. This is routine director compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: July 1, 2026; Filing date: July 2, 2026 (timely Form 4 filing).
• Price used: $4.34 per share (closing market price on July 1, 2026).
• Shares received: 2,650; total value reported: $11,501.
• Shares held in various trusts (Kenneth C. Anderson 2021 & 2015 Irrevocable Trusts, Kenneth and Cynthia Anderson Revocable Trusts); the reporting person disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest (Footnotes F3–F7).
• Notable footnotes: F1 — shares issued per director compensation policy and elected in lieu of cash; F2 — price based on closing market price; F3–F7 — trust ownership/disclaimer.
• No indication of option exercise, 10b5‑1 plan, tax withholding sale, or late filing in this report.

Context

• Director awards like this are standard compensation and do not necessarily reflect the director’s view of the company’s near‑term stock prospects. Unlike open‑market purchases, awards are part of routine pay and may be subject to company policies on holding periods.
• For retail investors, purchases (personal cash buys) are often viewed as a stronger signal than compensation awards; this filing should be interpreted as compensation disclosure rather than a direct insider investment decision.